Piper Jaffray analyst Danielle Brill believes Global Blood Therapeutics is now "significantly de-risked" after the FDA accepted its voxelotor new drug application filing for priority review and has no plans to hold an Advisory Committee meeting. The news reaffirms that the company and the FDA are aligned on voxelotor's regulatory path, and increases the probability of voxelotor's approval by its February 26, 2020 action date, Brill tells investors in a research note. The analyst remains bullish on Global Blood Therapeutics and keeps an Overweight rating on the shares with an $80 price target. The stock in early trading is up 12.5% to $53.42.